TAK-448
Also known as: Kisspeptin analog TAK-448, RVX-TAK-448, TAK448
Source TAK-448 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
TAK-448 is an investigational kisspeptin receptor agonist developed by Takeda Pharmaceutical. It has a unique dual-phase pharmacology: acute dosing stimulates gonadotropin release, while chronic/continuous dosing suppresses the HPG axis analogous to GnRH agonists. It has been studied for potential use in hormone-sensitive cancers (prostate cancer), hypogonadotropic hypogonadism, and other reproductive endocrine disorders.
Mechanism of Action
TAK-448 is a potent, long-acting synthetic kisspeptin analog that acts as a full agonist at the kisspeptin receptor (Kiss1R/GPR54). Sustained activation of Kiss1R initially stimulates GnRH pulsatile release, but chronic administration leads to receptor desensitization and downregulation of the hypothalamic-pituitary-gonadal (HPG) axis, suppressing LH, FSH, and sex steroid production.
Routes of Administration
Goals & Uses
- Stimulation of LH and FSH secretionReproductive EndocrinologyModerate
- Male infertilityReproductive EndocrinologyLow
- Treatment of hypogonadotropic hypogonadismEndocrinologyLow
- Testosterone suppression in prostate cancerOncologyModerate
Contraindications
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hormone-sensitive conditions where sex steroid stimulation is contraindicatedOncologyHigh
- Known hypersensitivity to kisspeptin analogsImmunologicalHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Decreased libido / sexual dysfunctionSexual HealthCommon
- Testosterone flareEndocrineCommon
- Hot flushesVasomotorCommon
- Bone mineral density reductionMusculoskeletalUncommon
Drug Interactions
- Antiandrogens (e.g., enzalutamide, bicalutamide)Low
- GnRH antagonists (e.g., degarelix)Moderate
- GnRH agonists (e.g., leuprolide)Moderate
Population Constraints
- Pediatric patientsAgeAbsolute
- Patients with severe renal or hepatic impairmentOrgan ImpairmentRelative
- Women of childbearing potentialReproductiveRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval; investigational status only.
- United StatesInvestigationalStudied in Phase I/II clinical trials; no FDA approval as of available data.
- United KingdomInvestigationalNo MHRA approval; investigational only.
TAK-448 has not received regulatory approval in any jurisdiction. It has been studied in Phase I/II clinical trials. Development status as of available data suggests it remains investigational.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is TAK-448?
TAK-448 is an investigational kisspeptin receptor agonist developed by Takeda Pharmaceutical. It has a unique dual-phase pharmacology: acute dosing stimulates gonadotropin release, while chronic/continuous dosing suppresses the HPG axis analogous to GnRH agonists. It has been studied for potential use in hormone-sensitive cancers (prostate cancer), hypogonadotropic hypogonadism, and other reproductive endocrine disorders.
What is TAK-448 used for?
TAK-448 is educationally associated with: Stimulation of LH and FSH secretion, Male infertility, Treatment of hypogonadotropic hypogonadism, Testosterone suppression in prostate cancer. Educational only — not medical advice.
How is TAK-448 administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of TAK-448?
Reported adverse effects include: Injection site reactions, Decreased libido / sexual dysfunction, Testosterone flare, Hot flushes, Bone mineral density reduction. This list is not exhaustive — consult a qualified clinician.
Who should avoid TAK-448?
Recorded contraindications: Pregnancy, Hormone-sensitive conditions where sex steroid stimulation is contraindicated, Known hypersensitivity to kisspeptin analogs. Consult a qualified clinician before use.